» Articles » PMID: 32800791

Medication Adherence: Importance, Issues and Policy: A Policy Statement from the American Heart Association

Overview
Date 2020 Aug 18
PMID 32800791
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Medications do not work in patients who do not take them. This true statement highlights the importance of medication adherence. Providers are often frustrated by the lack of consistent medication adherence in the patients they care for. Today with the time constraints that providers face, it becomes difficult to discover the extent of non-adherence. There are certainly many challenges in medication adherence not only at the patient-provider level but also within a healthy system and finally in insurers and payment systems. In a cross-sectional survey of unintentional nonadherence in over 24,000 adults with chronic illness, including hypertension, diabetes and hyperlipidemia, 62% forgot to take medications and 37% had run out of their medications within a year. These sobering data necessitate immediate policy and systems solutions to support patients in adherence. Medication adherence for cardiovascular diseases (CVD) has the potential to change outcomes, such as blood pressure control and subsequent events. The American Heart Association (AHA)/American Stroke Association (ASA) has a goal of improving medication adherence in CVD and stroke prevention and treatment. This paper will explore medication adherence with all its inherent issues and suggest policy and structural changes that must happen in order to transform medication adherence levels in the U.S. and achieve the AHA/ASA's health impact goals.

Citing Articles

Posttreatment Blood Pressure as a Key Predictor in a 5-Year Stroke Prediction Model.

Zhang N, Mei J, Fan F, Zhang Y, Zhou Z, Li J J Clin Hypertens (Greenwich). 2025; 27(1):e14974.

PMID: 39821957 PMC: 11771775. DOI: 10.1111/jch.14974.


Impact of Social Determinants of Health on Primary Adherence of Oral Anticoagulants Among Patients with Newly Diagnosed Atrial Fibrillation.

Glowacki N, Guzman I, Mills J, Parks A, Ateya M, Dai F Cardiol Ther. 2025; 14(1):53-69.

PMID: 39752004 PMC: 11893941. DOI: 10.1007/s40119-024-00395-0.


Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes.

Naoum I, Saliba W, Barnett-Griness O, Aker A, Zafrir B J Clin Med. 2024; 13(18).

PMID: 39337027 PMC: 11432281. DOI: 10.3390/jcm13185541.


Effectiveness of integrated management on hypertension and mortality in rural China: A CHHRS study.

Yu C, Shi Y, Zhao P, Wang T, Zhu L, Zhou W iScience. 2024; 27(10):110865.

PMID: 39319266 PMC: 11417325. DOI: 10.1016/j.isci.2024.110865.


Patient-pharmacist relationship dynamics: a mediation analysis of patient characteristics and reported outcomes.

Sacre H, Haddad C, Sakr F, Safwan J, Hajj A, Zeenny R J Pharm Policy Pract. 2024; 17(1):2371409.

PMID: 39015753 PMC: 11251441. DOI: 10.1080/20523211.2024.2371409.